Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,229 recruiting studies in this area right now.
By phase
- Not applicable3,142
- Phase 21,065
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4237
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)65
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona141
- New York123
- Massachusetts119
- Texas117
- Illinois82
- Colorado77
Recruiting studies6,229 total
- NCT04871191RecruitingPhase 3
Salvage treatment for granulomatosis with polyangiitis flare
This Phase 3 trial studies “salvage” treatment for people with active granulomatosis with polyangiitis (GPA) whose standard treatments have not worked well enough. It aims to improve disease control and reduce the need for ongoing higher-dose steroids.
ParisAges 18 years+ - NCT04871607RecruitingPhase 2
Yttrium antibody plus chemotherapy for hard-to-treat Hodgkin lymphoma
This trial studies a targeted antibody therapy with yttrium, combined with intensive chemotherapy, for adults whose Hodgkin lymphoma did not respond well or came back. It may help by delivering cancer-killing radiation directly to lymphoma cells and preparing the body for treatment after transplant conditioning.
Duarte, CaliforniaAges 18 years+ - NCT04872478RecruitingPhase 1
Early-phase drug safety and dosing study for relapsed blood cancers
This Phase 1 trial tests MRX-2843 in teenagers and adults whose leukemia has come back or did not respond to prior treatment. The main goals are to find safe dosing and learn how the body processes the drug.
Atlanta, GeorgiaAges 12 years+ - NCT04873492Recruiting
Study how genes and blood signals relate to MS outcomes
This study looks at genetic information and blood test signals to understand why some people with early MS develop a worse outcome. It may help doctors predict who is at higher risk and better understand disease mechanisms.
Nantes, Loire-AtlantiqueAges 18 years+ - NCT04875819RecruitingPhase 4
HIV vaccine safety check for meningitis and pneumonia shots
This trial studies how safe and how well the body’s immune system responds to meningococcal and pneumococcal vaccines in adults living with HIV. It may help confirm these vaccines work properly and are safe for people on HIV treatment.
HvidovreAges 18 years+ - NCT04876339Recruiting
Sound-based training to improve walking after brain illness
This study tests whether using special sounds (sonification) during gait training can improve walking for people with stroke, Parkinson’s disease, or multiple sclerosis. It may help your walking speed, stamina (fatigue), and overall walking pattern.
PaviaAges Up to 80 years - NCT04880200Recruiting
HIV testing at the clinic with help getting care
This study tests point-of-care lab tests that can find HIV-related virus levels quickly, and adds support to help people stay on treatment and connect to prevention services. If you are already HIV-positive and coming in for same-day lab testing, you may be able to get extra help with follow-through.
Seattle, WashingtonAges 18 years+ - NCT04881682RecruitingPhase 2
Testing blood-cleansing vs immunoglobulin for CIDP
This Phase 2 study compares a blood-cleansing treatment (immunoadsorption) with standard immune-boosting treatment (intravenous immunoglobulins) for chronic inflammatory demyelinating polyneuropathy (CIDP). It may help people whose steroid treatment did not work well, or who cannot take steroids.
Ulm, Baden-WurttembergAges 18 years+ - NCT04883437RecruitingPhase 2
Acalabrutinib plus obinutuzumab for slow-growing lymphoma
This Phase 2 study tests two medicines together—acalabrutinib and obinutuzumab—in people with previously untreated, slow-growing B-cell lymphomas. It aims to shrink the lymphoma and improve disease control, especially when tumor burden is low or when standard first treatments aren’t suitable.
Atlanta, GeorgiaAges 18 years+ - NCT04885179Recruiting
Study of SPLIS genetics and patient experiences
This observational study and patient registry collects information from people diagnosed with SPLIS due to specific changes in the SGPL1 gene, including children and newborns. It helps researchers understand the condition better and may improve future care and research planning.
San Francisco, CaliforniaAges Any age - NCT04888039Recruiting
Living with myeloma follow-up study in West-Occitanie
This study follows people with symptomatic multiple myeloma who live in the West-Occitanie region. It aims to better understand patients’ experiences and needs over time, which may help improve care and support.
Toulouse, West-OccitanieAges 18 years+ - NCT04886726RecruitingPhase 1
New medicine to prevent graft-versus-host disease after transplant
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
Detroit, MichiganAges 18–70 - NCT04888741RecruitingPhase 2
Trial testing reduced immune T cells before stem cell transplant
This Phase 2 trial looks at a transplant approach that reduces harmful immune cells (T cells) before or during an allogeneic stem cell transplant. It may help lower the risk of transplant complications while still letting the donor immune system fight the blood cancer.
Cardiff, WalesAges 16–70 - NCT04890483Recruiting
Brain stimulation to ease pain and fatigue after COVID
This study tests whether a noninvasive brain stimulation treatment can reduce fatigue and body pains after COVID in people with autoimmune diseases. It may help symptoms by changing brain activity without surgery.
São PauloAges 18–80 - NCT04891237RecruitingPhase 3
Grass and olive allergy vaccine trial for teens to older adults
This Phase 3 trial tests whether an allergy treatment can reduce symptoms caused by grass and olive pollen. It also checks safety, especially for breathing and allergic reactions, in people with confirmed grass/olive allergy.
Tarancón, CuencaAges 12–65 - NCT04892277RecruitingPhase 1
CD19 CAR-T for adults with hard-to-treat B-cell cancers
This Phase 1 trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell cancers have come back or did not respond to treatment. It may help your immune system better recognize and attack cancer cells, but it is early research, so benefits and risks are still being defined.
Rochester, MinnesotaAges 18 years+ - NCT04893564Recruiting
Testing blood DNA after 6 months of Waldenström treatment
This study looks at a blood test called circulating tumor DNA, measured after 6 months of treatment, to see how well it predicts outcomes in people with Waldenström macroglobulinemia. It may help doctors better judge who is responding and who may need treatment adjustments earlier.
AmiensAges 18 years+ - NCT04895436RecruitingPhase 2
Oral venetoclax plus IV obinutuzumab after prior CLL treatment
This trial tests whether adding oral venetoclax together with an IV antibody called obinutuzumab can control CLL when the disease comes back after a specific prior treatment. It also looks closely at side effects to see what changes in “disease activity” and safety to expect.
La Jolla, CaliforniaAges 18 years+ - NCT04898647Recruiting
Study of blood thickness in Waldenström’s disease
This study looks at “hyperviscosity,” meaning very thick blood, in people with Waldenström macroglobulinemia (WM). Your results may help doctors better understand who needs treatment and what tests should be used, even if thick blood is not found.
AmiensAges 18 years+ - NCT04898790Recruiting
Testing ways to improve thinking after bone marrow transplant
This study looks at whether a physical activity program and related study measures can improve thinking and memory in older adults around the time of a stem cell transplant. If you qualify and participate, the team will compare outcomes between groups to see what approach works best.
Omaha, NebraskaAges 19 years+ - NCT04898283RecruitingPhase 3
Allergy shot study for grass and cypress pollen symptoms
This phase 3 trial tests a specific allergy treatment (an “immunotherapy” shot) for people whose symptoms are triggered by grass and cypress tree pollen. It aims to see if the treatment is safer and more effective at reducing allergy symptoms over time, especially for nose/eye symptoms and some people with asthma.
Valladolid, Castille and LeónAges 12–65 - NCT04902443RecruitingPhase 1
Pomalidomide plus nivolumab for virus-related cancers
This trial studies pomalidomide plus nivolumab in people with cancers linked to certain viruses (or hepatitis B/C). It may help the immune system fight the cancer when the disease has returned, progressed, or can’t be fully treated with standard options.
Bethesda, MarylandAges 18–99 - NCT04902807Recruiting
Tool to help decide diagnosis and treatment in immune disorders
This trial tests a tool (a way of collecting health information) to help doctors make better diagnosis, prognosis, and treatment decisions for children with certain immune problems. It also includes healthy children (like relatives) as comparison groups, to see how well the tool works.
ParisAges 1–18 - NCT04904146Recruiting
Testing blood or tumor markers in skin lymphoma patients
This study looks for “predictive” and “prognostic” biomarkers—measurable signs in blood or tissue—to help predict how mycosis fungoides or Sézary syndrome will behave and how patients may respond to care. It may help doctors better understand outcomes for people with these skin lymphomas.
LundAges 18–100
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,229 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,721 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.